April 8, 2022
TPX-100: OrthoTrophix Presents New Data Suggesting Joint Bone Shape as a Possible Surrogate Marker for Virtual Joint Replacement in Knee Osteoarthritis
September 21, 2021
TPX-100: OrthoTrophix Published a New Research Article Demonstrating Disease Modification in Knee Osteoarthritis
May 12, 2020
TPX-100: OrthoTrophix Presents More Evidence for Disease Modification in Knee Osteoarthritis in a New Abstract Published in Osteoarthritis & Cartilage Journal
Welcome
OrthoTrophix is a biopharmaceutical company focused on development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone and cartilage. The primary focus of OrthoTrophix is development of a first-in-class disease modifying osteoarthritis drug (DMOAD). The company’s leading therapeutic compound,